NanoEncryption-protected drug a security milestone

The coming months should see the launch of a drug product that uses NanoGuardian's NanoEncryption brand protection technology. The launch, expected from a top-five drugmaker's candidate that is currently in review, will mark the first commercial use of the security technology, says SecuringPharma.

The technology provides unit-level protection against counterfeiting and diversion via three levels of security, as we've reported. The overt, covert and forensic security markings provide authentication and tracing data on capsules, tablets, vial caps, and single-use syringes.

NanoGuardian announced earlier this year that it had struck a licensing deal with Pfizer's Capsugel drug delivery division, enabling Capsugel to offer pre-coded capsule shells to its customers.

- see the article

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.